Medtronic (NYSE:MDT) Releases Q2 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its second quarter 2027 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.320-1.340 for the period, compared to the consensus EPS estimate of 1.350. The company issued revenue guidance of -. Medtronic also updated its FY 2027 guidance to 5.940-6.000 EPS.

Medtronic Price Performance

Shares of NYSE:MDT traded up $0.74 during midday trading on Tuesday, reaching $91.39. 5,695,199 shares of the company’s stock were exchanged, compared to its average volume of 8,818,341. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The firm has a market capitalization of $116.97 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. The company’s 50 day simple moving average is $85.81 and its two-hundred day simple moving average is $85.48. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts expect that Medtronic will post 5.94 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is currently 77.21%.

Analyst Upgrades and Downgrades

MDT has been the topic of several research reports. The Goldman Sachs Group cut their price target on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Evercore set a $105.00 price objective on shares of Medtronic in a research note on Monday, July 6th. Jefferies Financial Group reiterated a “hold” rating and issued a $88.00 price target on shares of Medtronic in a report on Thursday, June 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Medtronic in a research report on Tuesday, August 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $91.00 target price on shares of Medtronic in a report on Tuesday, August 18th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.79.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its fiscal 2027 guidance, increasing organic revenue growth expectations to 7.25%–7.75% and diluted non-GAAP EPS guidance to $5.94–$6.00. The company cited broad-based demand and strength in newer growth platforms. Medtronic boosts fiscal 2027 forecasts on heart device demand
• Positive Sentiment: Fiscal first-quarter revenue rose 13.7% to $9.756 billion, exceeding the $9.55 billion analyst consensus. Adjusted EPS was $1.45 versus expectations of $1.39, while GAAP net income was $1.47 billion and GAAP EPS was $1.14. Medtronic Q1 Revenue Rises 13.7% to $9.756 Billion, Raises FY27 Guidance
• Positive Sentiment: All major businesses posted strong growth: Cardiovascular revenue increased 19.5%, Neuroscience 10.3%, Medical Surgical 10.0%, and Diabetes 16.9% on a reported basis. Cardiovascular demand was especially strong in complex procedures. Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech and Robotics
• Positive Sentiment: Medtronic is investing more than $700 million in heart technology and robotics, including a strategic investment in Pi-Cardia to advance complex transcatheter aortic valve replacement procedures. The spending could strengthen longer-term growth but may increase near-term investment costs. Medtronic Announces Strategic Investment in Pi-Cardia
• Neutral Sentiment: An additional fiscal week contributed approximately $570 million to first-quarter organic revenue, creating a comparison benefit investors will need to consider when assessing the underlying growth rate.
• Negative Sentiment: Recent insider activity was entirely selling, with three reported open-market sales and no purchases over the past six months. Institutional positioning was also mixed, with major investors both adding to and reducing their holdings.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MDT. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 4th quarter valued at approximately $29,000. Imprint Wealth LLC acquired a new position in Medtronic during the third quarter worth $31,000. Chapman Financial Group LLC purchased a new position in shares of Medtronic during the second quarter worth $37,000. JPL Wealth Management LLC acquired a new stake in shares of Medtronic in the third quarter valued at $40,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Medtronic by 96.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock valued at $44,000 after buying an additional 223 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).